BR9913326A - Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação - Google Patents

Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação

Info

Publication number
BR9913326A
BR9913326A BR9913326A BR9913326A BR9913326A BR 9913326 A BR9913326 A BR 9913326A BR 9913326 A BR9913326 A BR 9913326A BR 9913326 A BR9913326 A BR 9913326A BR 9913326 A BR9913326 A BR 9913326A
Authority
BR
Brazil
Prior art keywords
cns
tumor
inhibitor
molecule
alginate
Prior art date
Application number
BR9913326A
Other languages
English (en)
Inventor
Rolf Bjerkvig
Original Assignee
Norsk Hydro As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Norsk Hydro As filed Critical Norsk Hydro As
Publication of BR9913326A publication Critical patent/BR9913326A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/126—Immunoprotecting barriers, e.g. jackets, diffusion chambers
    • A61K2035/128—Immunoprotecting barriers, e.g. jackets, diffusion chambers capsules, e.g. microcapsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)

Abstract

"CéLULA PRODUTORA ENCAPSULADA CAPAZ DE EXPRESSAR UMA MOLéCULA QUE SEJA UM INIBIDOR DO DESENVOLVIMENTO DE TUMOR NO CNS, MéTODO PARA O TRATAMENTO DE TUMOR DO CNS, E, USO DE UM ALGINATO DE IMUNOISOLAçãO" As células produtoras encapsuladas que são capazes de expressar uma molécula que é um inibidor do desenvolvimento do tumor do CNS fornecem um novo processo para o tratamento de tumores, tais como os tumores cerebrais que estão localizados dentro do sistema nervoso central.
BR9913326A 1998-08-26 1999-08-25 Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação BR9913326A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO983911A NO983911D0 (no) 1998-08-26 1998-08-26 Alginatkapsler til bruk ved behandling av hjernesvulst
PCT/NO1999/000266 WO2000012066A1 (en) 1998-08-26 1999-08-25 Alginate capsules for use in the treatment of brain tumour

Publications (1)

Publication Number Publication Date
BR9913326A true BR9913326A (pt) 2001-05-15

Family

ID=19902361

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9913326A BR9913326A (pt) 1998-08-26 1999-08-25 Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação

Country Status (16)

Country Link
US (2) US6926888B1 (pt)
EP (1) EP1105100A1 (pt)
JP (1) JP2002523445A (pt)
KR (1) KR100699286B1 (pt)
CN (1) CN1191823C (pt)
AU (1) AU760433B2 (pt)
BR (1) BR9913326A (pt)
CA (1) CA2340325A1 (pt)
IL (2) IL141501A0 (pt)
IS (1) IS5855A (pt)
NO (2) NO983911D0 (pt)
NZ (1) NZ510167A (pt)
RU (1) RU2229287C2 (pt)
TR (1) TR200100583T2 (pt)
WO (1) WO2000012066A1 (pt)
ZA (1) ZA200101464B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1053329T3 (da) * 1998-02-03 2010-01-25 Ct Disease Contr & Prevention Rekombinant lipideret PsaA-protein, fremgangsmåder til fremstilling og anvendelse
SE530184C2 (sv) * 2005-12-23 2008-03-18 Kjell Stenberg Bioadhesiv farmaceutisk filmkomposition innehållande lågviskösa alginater
KR100969516B1 (ko) * 2007-08-16 2010-07-09 경북대학교 산학협력단 세포 생존력 및 기능을 향상시키는 도우넛형 세포 캡슐의제조 방법 및 세포 치료적용
US9555007B2 (en) * 2013-03-14 2017-01-31 Massachusetts Institute Of Technology Multi-layer hydrogel capsules for encapsulation of cells and cell aggregates

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5073491A (en) * 1988-12-23 1991-12-17 Hoffman-La Roche Inc. Immobilization of cells in alginate beads containing cavities for growth of cells in airlift bioreactors
US5459054A (en) * 1989-12-05 1995-10-17 Neocrin Company Cells encapsulated in alginate containing a high content of a- l- guluronic acid
US5166137A (en) 1991-03-27 1992-11-24 Nobipols Forskningsstiftelse Guluronic acid polymers and use of same for inhibition of cytokine production
WO1992019195A1 (en) 1991-04-25 1992-11-12 Brown University Research Foundation Implantable biocompatible immunoisolatory vehicle for delivery of selected therapeutic products
US5286495A (en) * 1992-05-11 1994-02-15 University Of Florida Process for microencapsulating cells
ATE172099T1 (de) 1994-07-08 1998-10-15 Baxter Int Implantierte vorrichtung mit tumorzellen zur behandlung von krebs
US6126936A (en) * 1995-03-10 2000-10-03 Biohybrid Technologies Llc Microcapsules and composite microreactors for immunoisolation of cells
US5854205A (en) * 1995-10-23 1998-12-29 The Children's Medical Center Corporation Therapeutic antiangiogenic compositions and methods
WO1997036495A1 (en) 1996-04-03 1997-10-09 The Rogosin Institute Implantable agarose-collagen beads containing cells which produce a diffusible biological product, and uses thereof
WO1997038707A1 (en) * 1996-04-17 1997-10-23 Cytotherapeutics, Inc. Method and device for delivery of apoptosis-inducing molecules
US6027721A (en) 1996-05-20 2000-02-22 Cytotherapeutics, Inc. Device and method for encapsulated gene therapy
DE19638745C2 (de) * 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
US6368612B1 (en) * 1997-12-12 2002-04-09 Biohybrid Technologies Llc Devices for cloaking transplanted cells

Also Published As

Publication number Publication date
JP2002523445A (ja) 2002-07-30
CN1191823C (zh) 2005-03-09
IS5855A (is) 2001-02-22
US20050180960A1 (en) 2005-08-18
ZA200101464B (en) 2002-05-21
WO2000012066A1 (en) 2000-03-09
CA2340325A1 (en) 2000-03-09
AU5538999A (en) 2000-03-21
NZ510167A (en) 2003-09-26
US6926888B1 (en) 2005-08-09
RU2229287C2 (ru) 2004-05-27
NO983911D0 (no) 1998-08-26
NO20010960D0 (no) 2001-02-26
NO20010960L (no) 2001-04-25
AU760433B2 (en) 2003-05-15
EP1105100A1 (en) 2001-06-13
IL141501A (en) 2006-10-31
KR20010074851A (ko) 2001-08-09
TR200100583T2 (tr) 2001-06-21
KR100699286B1 (ko) 2007-03-26
CN1320032A (zh) 2001-10-31
IL141501A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
BR0113235A (pt) Composições e métodos para a terapia e a diagnose de malignidades associadas com her-2/neu
BR9910251A (pt) Estimulação hematopoiética
ES2147720T3 (es) Factor de celulas madre.
DE59601880D1 (de) Verfahren zur herstellung hydrophiler oder teilweise hydrophiler, anorganischer aerogele
BR9812122A (pt) Combinação de inibidor da tirosina quinase e castração quìmica para tratar câncer da próstata
ES2169095T3 (es) Proteinas con actividad de factor viii, procedimiento para su produccion utilizando celulas modificadas por ingenieria genetica y composiciones farmaceuticas que los contienen.
PA8447801A1 (es) Derivados del acido hexanoico
ATE402698T1 (de) Verwendung von ppar-gamma aktivatoren zur behandlung von hautkrankheiten
IS1904B (is) Hliðstæðar aðferðir við framleiðslu á nýjum (R)-5-karbamóýl-8-flúor-3-N,N-tvíútskiptum-amínó-3,4-díhýdró-2H-1-bensópýrönum
ATE258796T1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
BR9809284A (pt) Construto e processo para expressão de polinucleotìdeo em altos nìveis
BR0007759A (pt) Composto, processo para preparar o mesmo,composição farmacêutica, e, métodos para tratarcondições de doença mediadas pelametaloproteinase de matriz em um mamìfero emnecessidade deste, e para tratar um paciente quesofre de uma condição selecionada do grupo queconsiste de osteoartrite, artrite reumatóide,perda de cartilagem degenerativa edesenvolvimento de tumor
BR9914907A (pt) Cápsula mineral, processo para sua preparação, e, utilização das cápsulas
DE3370320D1 (en) Aminocyclohexanol derivatives having an expectorant activity, process for their preparation and pharmaceutical compositions containing them
ES2158938T3 (es) Derivados de aminoquinazolina que tienen actividad alfa-antagonistas.
BR9913326A (pt) Célula produtora encapsulada capaz de expressar uma molécula que seja um inibidor do desenvolvimento de tumor no cns, método para o tratamento de tumor do cns, e, uso de um alginato de imunoisolação
DE69934987D1 (de) Ein präkursor der harnsäure und ein antioxidationsmittel enthaltende zusammensetzung und deren verwendung zur behandlung von neurodegenerativen erkrankungen
BR8202494A (pt) Processo para preparar tecido natural fixo bem como tecido natural fixo valvula cardiaca fixa de suino e tecido fixo de pericardio de bovino adequados para implante
BR9816100A (pt) Processo para produção de fosfatìdios desoleados
HUP9802531A2 (hu) Eljárás haematopoeticus stem sejtek mobilizálására
ES2007328A4 (es) Derivados de dihidropiridazinona, proceso de fabricacion y medicamentos con sus combinaciones
MY107354A (en) Substituted cyclohexenes as central nervous system agents
ES2044876T3 (es) Compuestos de reaccion por adicion, procedimiento para su produccion y su utilizacion.
ATE310100T1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität
MX9301017A (es) Microesfera de acido graso que contiene enterococcus para usarse en mejorar el crecimiento y la calidad del caparazon.

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Free format text: FMC BIOPOLYMER AS (NO)

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: INDEFIRO O PRESENTE PEDIDO DE PATENTE DE ACORDO COM ART. 8O DA LPI.

B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.